Investigational drug · Phase 2
DKN-01
Also called: LY2812176
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
14
Any phase or sponsor naming "DKN-01"
First trial start
2022
Aug 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DKN-01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer
- Colorectal Adenocarcinoma
- Colo-rectal Cancer
- Colorectal Cancer Metastatic
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "DKN-01" as an intervention, largest first.
- A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal CancerPivotal-lookingTerminated
Leap Therapeutics, Inc.Industry
NCT04363801 · 247 participants · Start Jul 29, 2020 · Primary completion Mar 31, 2025
Drug: DKN-01 300mg; DKN-01 600mg and 7 more · For: Gastric Cancer; Gastric Adenocarcinoma; GastroEsophageal Cancer
Sites: Phoenix, Arizona; Tucson, Arizona; Duarte, California · 48 sites in all
- Phase 2 Study of DKN-01 in Colorectal CancerPivotal-lookingCompleted
Leap Therapeutics, Inc.Industry
NCT05480306 · 188 participants · Start Aug 30, 2022 · Primary completion Jul 10, 2025
Drug: DKN-01; FOLFIRI and 2 more · For: Colorectal Cancer; Colorectal Adenocarcinoma; Colo-rectal Cancer and 1 more
Sites: Tucson, Arizona; Los Angeles, California; Cape Coral, Florida · 40 sites in all
Leap Therapeutics, Inc.Industry
NCT02013154 · 151 participants · Start May 5, 2014 · Primary completion Jul 19, 2019
Drug: DKN-01 150 mg; Paclitaxel and 2 more · For: Esophageal Neoplasms; Adenocarcinoma of the Gastroesophageal Junction; Gastroesophageal Cancer and 2 more
Sites: Los Angeles, California; New Haven, Connecticut; Chicago, Illinois · 10 sites in all
Leap Therapeutics, Inc.Industry
NCT03395080 · 111 participants · Start Mar 5, 2018 · Primary completion Sep 9, 2020
Drug: Paclitaxel; 300mg DKN-01 and 1 more · For: Endometrial Cancer; Uterine Cancer; Ovarian Cancer and 1 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; West Palm Beach, Florida · 17 sites in all
- DKN-01 Inhibition in Advanced Liver CancerStatus unknown
Johannes Gutenberg University MainzAcademic, hospital or other
NCT03645980 · 70 participants (planned) · Start Oct 10, 2018 · Primary completion Aug 31, 2021
Drug: DKN-01 300 mg; DKN-01 600 mg and 1 more · For: Hepatocellular Carcinoma
Sites: Cologne, Germany; Hamburg, Germany; Hanover, Germany · 6 sites in all
- WaKING: Wnt and checKpoint INhibition in Gastric CancerActive, not recruiting
Royal Marsden NHS Foundation TrustAcademic, hospital or other
NCT04166721 · 52 participants (planned) · Start Feb 11, 2020 · Primary completion Mar 30, 2025
Drug: Atezolizumab · For: Metastatic Esophageal Cancer; Metastatic Gastric Cancer
Sites: Sutton, United Kingdom
Leap Therapeutics, Inc.Industry
NCT02375880 · 51 participants · Start Jun 2015 · Primary completion Jul 2018
Drug: DKN-01; gemcitabine and 1 more · For: Carcinoma of Intrahepatic and Extra-hepatic Biliary System; Carcinoma of Gallbladder; Bile Duct Cancer and 1 more
Sites: Los Angeles, California; New Haven, Connecticut; Boston, Massachusetts · 9 sites in all
Leap Therapeutics, Inc.Industry
NCT01457417 · 32 participants · Start Jan 2012 · Primary completion Dec 2013
Drug: DKN-01 · For: Multiple Myeloma; Solid Tumors; Non-Small Cell Lung Cancer
Sites: Scottsdale, Arizona; Albany, New York; Greenville, South Carolina · 8 sites in all
NYU Langone HealthAcademic, hospital or other
NCT03837353 · 18 participants · Start Apr 1, 2019 · Primary completion Jul 19, 2022
Drug: DKN-01; Docetaxel · For: Prostate Cancer
Sites: San Francisco, California; Baltimore, Maryland; St Louis, Missouri · 5 sites in all
Massachusetts General HospitalAcademic, hospital or other
NCT04057365 · 15 participants · Start Oct 7, 2019 · Primary completion Sep 25, 2022
Drug: Nivolumab; DKN-01 · For: Biliary Tract Cancer
Sites: Boston, Massachusetts · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial.
Gordon A, Cartwright E, Tran A, et al. · ESMO Gastrointest Oncol 2026
- The Dickkopf-1 (DKK1) Dichotomy in Oncology: New Insights on Tumor Progression and Immune Regulation.
Canella A, Gentry Z, Cosgrove C · Int J Mol Sci 2026
- Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.
Lee KW, Mahalingam D, Shim BY, et al. · Nat Commun 2026
- Overcoming antigen tolerance to develop GB22-45-2, an anti-DKK1 antibody for gastric cancer.
Zhang W, Wei X, Yao T, et al. · Antib Ther 2025
- DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.
Lee KW, Mahalingam D, Shim BY, et al. · Nat Commun 2025
- A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Wise DR, Pachynski RK, Denmeade SR, et al. · Prostate Cancer Prostatic Dis 2025
Also in development for Colorectal Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.